Strategic Partnerships Abpro has established strategic partnerships with global pharmaceutical companies to develop innovative antibody therapies for severe diseases, creating potential collaborative sales opportunities.

Recent IPO Recently going public, Abpro has secured funding for clinical trials of lead antibody drugs, indicating potential growth and investment opportunities for sales development.

Focusing on Immuno-Oncology With a strong focus on immuno-oncology, Abpro is developing cutting-edge antibody treatments for cancer, presenting sales prospects in the oncology market segment.

Expansion in Ophthalmology Expanding into ophthalmology, Abpro is developing antibody therapies for vascular eye diseases, signaling a potential entry point for sales targeting eye care professionals and facilities.

Global Reach By collaborating with international biotech firms like Celltrion in South Korea, Abpro has a global presence, offering wider sales reach and cross-border sales opportunities.